Active Clinical Trials

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

By April 24, 2017 No Comments


Malignant Pleural Mesothelioma

Estimated Enrollment: 390

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Study ID Numbers: NGR015|2009-016879-29

Study First Received: March 17, 2010

Last Updated: October 8, 2015

Estimated Primary Completion Date: December 2016


Primary Outcome Measures:

Overall Survival (OS)|Progression-Free Survival (PFS)|Disease Control Rate (DCR)|Duration of Disease Control|Safety and Toxicity according to NCI-CTCAE criteria (version 4.02)|Quality of life (QoL) according to Lung Cancer Symptom Scale|Evaluation of medical care utilization in the two treatment arms

Sponsors and Collaborators:

MolMed S.p.A.

Website Link:

Leave a Reply

Call Now ButtonCall Now